ReAlta secures FDA orphan drug and fast track designations for GvHD therapy
ReAlta’s pegtarazimod is being developed to treat acute graft-versus-host disease (GvHD) for patients unresponsive to steroid therapies.
ReAlta’s pegtarazimod is being developed to treat acute graft-versus-host disease (GvHD) for patients unresponsive to steroid therapies.
What's Your Reaction?
